Standalone notes that expand on individual findings from the Infusion Reimbursement Index in more depth than the main report has room for.
Price, prior auth, site-of-care steering, and the pharmacy channel, drug by drug across all 36 dossier drugs, plus the infliximab formulary-tiering grid payer by payer.
Commercial contracted rates for the six Part B drugs selected for Medicare price negotiation, captured before the negotiated Maximum Fair Price replaces ASP+6% in 2028.
Why the widely cited 30%+ hospital-outpatient premium over office infusion mostly reflects different billing forms once the same billing form is compared on both sides.
Contracted rates from insurers’ machine-readable files, not amounts paid on a claim. Figures are drawn from report_data.json published alongside the Infusion Reimbursement Index.